Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 191.74 | 338.77 | - | - | - |
Total Expenses | 192.51 | 300.64 | - | - | - |
Profit Before Tax | -0.77 | 38.14 | - | - | - |
Profit After Tax | 0.32 | 29 | - | - | - |
Operating Profit after Depreciation | -0.69 | 38.39 | - | - | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 50.05 | 48.12 | - | - | - |
Total Non Current Assets | 117.14 | 62.39 | - | - | - |
Total Current Assets | 225.54 | 150.58 | - | - | - |
TOTAL ASSETS | 342.69 | 212.97 | - | - | - |
Total Shareholder's Fund | 236.86 | 100.49 | - | - | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 1.89 | 56.05 | - | - | - |
Net Cash used in Investing Activities | -143.88 | -55.17 | - | - | - |
Net Cash used in Financing Activities | 152.45 | -0.93 | - | - | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 191.73 | 338.77 | 293.47 | 183.78 | - |
Total Expenses | 192.49 | 300.64 | 251.77 | 136.76 | - |
Profit Before Tax | -0.75 | 38.14 | 41.70 | 47.02 | - |
Profit After Tax | 0.34 | 29 | 27.50 | 30.59 | - |
Operating Profit after Depreciation | -0.67 | 38.39 | 41.78 | 48.81 | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 31.61 | 29.97 | 22.23 | 19.79 | - |
Total Non Current Assets | 115.46 | 30.80 | 25.02 | 20.42 | - |
Total Current Assets | 209.27 | 181.96 | 156.80 | 85.89 | - |
TOTAL ASSETS | 324.73 | 212.76 | 181.81 | 106.31 | - |
Total Shareholder's Fund | 236.88 | 100.49 | 71.46 | 88.58 | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 48.78 | 22.96 | 2.25 | 9.11 | - |
Net Cash used in Investing Activities | -182.73 | -21.18 | -12.24 | -16.67 | - |
Net Cash used in Financing Activities | 135.80 | -1.53 | 6.18 | 11.43 | - |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 35.23 | 21.48 | 18.88 | 30.59 | 40.52 |
Total Expenses | 34.61 | 28.22 | 21.28 | 35.12 | 46.83 |
Profit Before Tax | 1.62 | -3.91 | -0.17 | -2.57 | -5.04 |
Profit After Tax | 2.35 | -4.74 | -0.51 | -1.24 | -3.50 |
Operating Profit after Depreciation | 2.20 | -3.38 | 0.41 | -2.03 | -4.53 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 35.23 | 21.48 | 18.88 | 30.58 | 40.52 |
Total Expenses | 34.60 | 28.22 | 21.28 | 35.12 | 46.83 |
Profit Before Tax | 0.73 | -5.33 | -0.78 | -2.56 | -5.04 |
Profit After Tax | 1.60 | -5.98 | -1.01 | -1.22 | -3.50 |
Operating Profit after Depreciation | 1.30 | -4.81 | -0.23 | -2.04 | -4.53 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Valiant Laboratories Ltd | ₹91.15 | ₹396.05 |
Sun Pharmaceuticals Industries Ltd | ₹1,613.65 | ₹3,87,168.69 |
Divis Laboratories Ltd | ₹5,725.20 | ₹1,51,986.07 |
Cipla Ltd | ₹1,463.25 | ₹1,18,174.12 |
Torrent Pharmaceuticals Ltd | ₹3,028.40 | ₹1,02,490.21 |
Mankind Pharma Ltd | ₹2,337.05 | ₹96,421.67 |
On 7 February 2025
01 Feb 2025, 12:32 pm
On 12 November 2024
08 Nov 2024, 12:22 pm
On 12 August 2024
09 Aug 2024, 03:05 pm
On 8 August 2024
18 Jul 2024, 04:22 pm
On 14 May 2024
07 May 2024, 02:03 pm